Suggested remit - To appraise the clinical and cost effectiveness of liraglutide within its marketing authorisation, in addition to diet and physical activity, for the management of people with obesity or overweight with risk factors
Status Proposed
Process STA 2018
ID number 740

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
21 September 2018 - 19 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance